David Karsenti
Charenton-le-Pont, Île-de-France Region, 94220, France
NCT Number: NCT03567863
Multicenter randomized prospective study
Criteria for inclusion:
Patients admitted for EUS-FNB of a pancreatic mass
Goals of the study:
To compare the results of blinded punctures for suspicion of pancreatic tumor performed under endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific.
Main criterion:
- Biopsy core length of target tissue obtained by needle pass
Number of patients:
60 patients
Duration of the study:
1 year
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Charenton-le-Pont, Île-de-France Region, 94220, France
Type of study:
Multicenter randomized prospective study
Criteria for inclusion:
Patients admitted for ENDOSCOPIC ULTRASOUND FINE NEEDLE BIOPSY (EUS-FNB) of a pancreatic mass
Exclusion criteria
Patients with an extra-pancreatic mass puncture Echendoscopic puncture contraindication or vascular interposition
Goals of the study:
To compare the results of blinded punctures for suspicion of pancreatic tumor performed under endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific.
Evaluation criteria :
Main criterion:
Secondary criteria
Number of patients:
60 patients
Duration of the study:
1 year
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
Time frame: in the 7 days after procedure
cumulative length of tissue core biopsies per needle pass in mm
Time frame: in the 7 days after procedure
Presence of core biopsy specimen
Time frame: in the 7 days or 6 months
EUS-FNB Sensitivity for the diagnosis of adenocarcinoma of the pancreas
Time frame: in the 7 days or 6 months
EUS-FNB Specificity for the diagnosis of adenocarcinoma of the pancreas
Time frame: in the 7 days or 6 months
EUS-FNB Positive predictive value for the diagnosis of adenocarcinoma of the pancreas
Time frame: in the 7 days or 6 months
EUS-FNB Negative Predictive Value for the diagnosis of adenocarcinoma of the pancreas
Time frame: 6 months
Computer Aided Morphometric Evaluation of the Tumor + Stroma Surface on All Core biopsies
Time frame: 6 months
Success rate of isolation of tumor cells
Time frame: 7 days
Puncture Morbidity (acute pancreatitis, haemorrhage)
Time frame: during procedure
Technical failure rate of puncture because of a impossibility to access to pancreatic mass with the needle (due to the needle stiffness)
Time frame: 7 days
inter evaluation of the anatomopathological criteria used (presence of a biopsy core, length of target tissue core per needle pass)
Time frame: 6 months
determination of transcriptomic signatures of pancreatic adenocarcinoma subtypes
Time frame: 7 days
intra-observer evaluation of the anatomopathological criteria used
Société Française d'Endoscopie Digestive
Other
Multicentric Randomized Study Comparing the Histological and Molecular Material Quality Obtained by EUS-FNB of Pancreatic Mass With Two "Biopsic" Needles: the 20-gauge Procore® (Cook) and the 22-gauge Acquire® (Boston Scientific)
Acronym: HISTOPAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04257448
Digestive System Diseases, Digestive System Neoplasms
Cologne, Germany
View Trial DetailsNCT05351983
Digestive System Diseases, Digestive System Neoplasms
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT04436679
Digestive System Diseases, Digestive System Neoplasms
Lille, France
View Trial DetailsNCT03871790
Colo-rectal Cancer, Colon Adenocarcinoma
Lahore, Pakistan
View Trial Details